Clinical Trials Browser

Phase 2 × Active not recruiting × umbralisib × Clear all

NCT03269669 2026-03-19

Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma

Phase 2 Active not recruiting

Lymphoma, Follicular